Medication info

Glitamen Tablet 15/850 mg

Prescription medicationTabletExpired
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Saehan Pharmaceutical Co., Ltd.
Appearance
White to grayish-white rectangular film-coated tablet
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Expired

MFDS item code 201903774 · Approved 2019.06.07

This product's status changed to Expired on 2024.06.07. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
In the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start with their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching to this drug from other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. After administering this drug to a patient, or when increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is required to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG does not worsen, administration for an adequate period (8-12 weeks) to evaluate changes in HbA1C is recommended.

Ingredients

Manufacturer
Saehan Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-independent diabetes
  • blood sugar control disorder
  • type 2 diabetes
View approved original text

This drug is used to help control blood sugar levels in patients with insulin-independent diabetes, namely type 2 diabetes. It is especially used when sufficient control of blood sugar is difficult with monotherapy using metformin or pioglitazone while following dietary and exercise therapies. It can also replace the combination therapy of pioglitazone and metformin. Management of type 2 diabetes is very important with nutritional counseling, weight loss, and regular exercise, as these lifestyle therapies greatly help maintain the efficacy of drug treatment. This drug is used to improve blood sugar control in the treatment of type 2 diabetes.

Dosage and Administration

Adult dosage

In the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start with their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching to this drug from other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. After administering this drug to a patient, or when increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is required to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG does not worsen, administration for an adequate period (8-12 weeks) to evaluate changes in HbA1C is recommended.

Precautions

This drug consists of two components that help lower blood sugar. The first component may cause a rare side effect called lactic acidosis, in which excess lactic acid builds up in the body; this condition can be very serious and life-threatening if untreated. Therefore, patients with reduced kidney function or problems with the heart or lungs, and those with sepsis or dehydration should not use this drug or should do so with extreme caution. Additionally, patients with impaired liver function should not take this drug. Excessive alcohol consumption may increase the risk of side effects, so alcohol should be avoided during treatment. The second component can worsen heart failure, so patients with poor heart function should not use this drug. If symptoms of heart failure occur, consult a doctor immediately, and the dosage may need to be adjusted or stopped if necessary. This component may also cause fluid retention, leading to swelling or weight gain, so caution is advised. Patients with a history of bladder cancer or those currently with active bladder cancer should not be administered this drug. If any abnormal symptoms such as hematuria or urinary disorders occur during treatment, notify a doctor immediately. Pregnant or breastfeeding women should not take this drug, and safety in pediatric patients has not been established. Elderly patients may have reduced kidney function, so the dosage of this drug should be determined carefully, and kidney function should be monitored regularly. During treatment with this drug, regular monitoring of blood glucose, blood tests, liver function tests, and kidney function tests should be performed, and it is recommended to also check vitamin B12 levels. If symptoms of hypoglycemia or early symptoms of lactic acidosis (such as difficulty breathing, muscle pain, fatigue, altered consciousness, etc.) occur, stop taking this drug immediately and inform healthcare personnel. Additionally, this drug may interact with other medications, so inform healthcare personnel of any other medications being taken, and treatment with this drug may need to be temporarily discontinued before and after surgery. Lastly, it is important to combine dietary and exercise therapies for normal blood sugar control, and safe intake should be ensured through regular check-ups and consultations with healthcare personnel.

Side effects

Lactic acidosis, hypoglycemia, fatigue, myalgia, dyspnea, weakness, abdominal pain, hypothermia, hypotension, resistant bradyarrhythmia, upper respiratory tract infection, diarrhea, composite edema, peripheral edema, headache, nausea, urinary tract infection, sinusitis, dizziness, lower limb edema, weight gain, myalgia, dental disorders, worsening of diabetes, pharyngitis, anemia, decreased vision, diabetic macular edema, liver failure, congestive heart failure, dyspepsia, insomnia, dry mouth, constipation, abdominal distension, abnormal blood sugar, arthralgia, increased serum creatinine, increased serum urea, fracture, hypoglycemia, elevated serum transaminase levels, elevated serum creatine phosphokinase levels, urination disorders, urgency to urinate

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to protect it from air and moisture. It is also advisable to keep the drug at room temperature between 1 and 30 degrees Celsius, avoiding too hot or too cold places.

Appearance and packaging

Appearance

White to grayish-white rectangular film-coated tablet

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.